Research programme: protein therapeutics - Ansun Biopharma

Drug Profile

Research programme: protein therapeutics - Ansun Biopharma

Alternative Names: ANSX109/142; ANSX98; Sepcidin; Viradin

Latest Information Update: 04 Aug 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NexBio
  • Developer Ansun Biopharma
  • Class Proteins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections; Viral haemorrhagic fevers
  • Discontinued Sepsis; Septic shock

Most Recent Events

  • 04 Aug 2015 Preclinical development is ongoing for bacterial infections and viral haemorrhagic fevers in USA
  • 04 Aug 2015 Discontinued for Septic shock in USA (IV)
  • 27 Jul 2015 Discontinued for Sepsis in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top